Evogene (EVGN) Non-cash Items (2013 - 2026)
Evogene (EVGN) posted Non-cash Items of $2.8 million for Q1 2026, down 6.2% sequentially from $3.0 million in Q4 2025, and up 274.86% YoY from $738413.2 in Q1 2025.
Evogene (EVGN) Non-cash Items (2013 - 2026) Analysis & Trends
Evogene has reported Non-cash Items for 14 years, with the latest figure at $2.8 million in Q1 2026.
- Quarterly Non-cash Items rose 274.86% year-over-year to $2.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $6.3 million (up 282.83% YoY) and the FY2025 annual result came in at $3.2 million, up 441.9% from the prior year.
- Non-cash Items eased to $2.8 million in Q1 2026 per EVGN's latest filing, from $3.0 million in the prior quarter.
- Over five years, Non-cash Items peaked at $3.1 million in Q2 2022 and troughed at -$4.5 million in Q4 2024.
- A 5-year average of $566352.9 and a median of $942000.0 in 2022 frame the typical range for Non-cash Items.
- The sharpest annual moves came in 2022 and 2024: Non-cash Items jumped 602.04% in 2022, then plunged 861.19% in 2024.
- Over 5 years, Non-cash Items stood at $942000.0 in 2022, then plunged by 37.37% to $590000.0 in 2023, then slumped by 861.19% to -$4.5 million in 2024, then surged by 165.71% to $3.0 million in 2025, then retreated by 6.2% to $2.8 million in 2026.
- According to Business Quant data, Non-cash Items over the past three periods registered $2.8 million, $3.0 million, and -$423000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Evogene | 4.38 Mn | 4.38 Mn | 204,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 2.77 Mn |
| Mar 31, 2026 | 2.77 Mn |
| Dec 31, 2025 | 2.95 Mn |
| Dec 31, 2025 | 2.95 Mn |
| Sep 30, 2025 | -423,000.00 |
| Sep 30, 2025 | -423,000.00 |
| Jun 30, 2025 | 986,000.00 |
| Jun 30, 2025 | 986,000.00 |
| Mar 31, 2025 | -1.58 Mn |
| Mar 31, 2025 | -1.58 Mn |
| Dec 31, 2024 | -4.49 Mn |
| Dec 31, 2024 | -4.49 Mn |
| Sep 30, 2024 | 1.99 Mn |
| Sep 30, 2024 | 1.99 Mn |
| Jun 30, 2024 | 646,000.00 |
| Jun 30, 2024 | 646,000.00 |
| Mar 31, 2024 | -1.92 Mn |
| Mar 31, 2024 | -1.92 Mn |
| Dec 31, 2023 | 590,000.00 |
| Dec 31, 2023 | 590,000.00 |